Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2944) 2944
Book Chapter (17) 17
Dissertation (17) 17
Publication (4) 4
Web Resource (4) 4
Magazine Article (2) 2
Book Review (1) 1
Conference Proceeding (1) 1
Newspaper Article (1) 1
Paper (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
meropenem (2662) 2662
science & technology (1846) 1846
life sciences & biomedicine (1689) 1689
humans (1268) 1268
infectious diseases (853) 853
microbiology (850) 850
antibiotics (820) 820
pharmacology & pharmacy (767) 767
microbial sensitivity tests (613) 613
anti-bacterial agents - pharmacology (575) 575
imipenem (560) 560
male (557) 557
biological and medical sciences (545) 545
medical sciences (519) 519
female (505) 505
drug resistance (497) 497
pharmacology. drug treatments (435) 435
bacteria (430) 430
thienamycins - pharmacology (429) 429
antibacterial agents (424) 424
antimicrobial agents (370) 370
antibiotics. antiinfectious agents. antiparasitic agents (369) 369
anti-bacterial agents - therapeutic use (357) 357
middle aged (354) 354
infections (341) 341
adult (333) 333
aged (322) 322
carbapenems (305) 305
thienamycins - therapeutic use (283) 283
hospitals (278) 278
patients (264) 264
biochemical phenomena, metabolism, and nutrition (250) 250
pseudomonas aeruginosa (239) 239
pathogens (235) 235
carbapenems - pharmacology (232) 232
ceftazidime (231) 231
bacterial infections and mycoses (230) 230
e coli (228) 228
antibiotic resistance (227) 227
anti-bacterial agents - administration & dosage (223) 223
polycyclic compounds (211) 211
thienamycins - administration & dosage (206) 206
treatment outcome (206) 206
ciprofloxacin (205) 205
colistin (200) 200
pneumonia (199) 199
piperacillin (192) 192
pseudomonas aeruginosa - drug effects (191) 191
imipenem - pharmacology (189) 189
analysis (182) 182
drug resistance in microorganisms (182) 182
mortality (182) 182
antimicrobial resistance (179) 179
minimum inhibitory concentration (178) 178
cefepime (177) 177
amikacin (175) 175
carbapenemase (175) 175
health aspects (175) 175
laboratories (174) 174
vancomycin (174) 174
animals (171) 171
medicine (170) 170
pharmacokinetics (167) 167
ertapenem (166) 166
tazobactam (165) 165
thienamycins - pharmacokinetics (161) 161
beta-lactamases - metabolism (155) 155
beta-lactamases - genetics (153) 153
klebsiella (152) 152
research article (152) 152
gram-negative bacteria (145) 145
anti-bacterial agents - pharmacokinetics (139) 139
drug resistance, bacterial (137) 137
genes (136) 136
risk factors (136) 136
adolescent (135) 135
immunology (135) 135
research (134) 134
aged, 80 and over (132) 132
beta lactam antibiotics (131) 131
nosocomial infections (131) 131
clinical isolates (130) 130
science & technology - other topics (130) 130
epidemiology (129) 129
multidisciplinary sciences (129) 129
internal medicine (128) 128
bacterial infections (127) 127
ampicillin (124) 124
pharmacology (124) 124
meropenem - pharmacology (123) 123
multidrug resistance (123) 123
gentamicin (122) 122
carbapenem (121) 121
infection (121) 121
sepsis (119) 119
drug therapy, combination (118) 118
antiinfectives and antibacterials (116) 116
science (116) 116
pediatrics (115) 115
polymerase chain reaction (114) 114
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2842) 2842
Japanese (52) 52
Chinese (49) 49
Spanish (36) 36
Portuguese (27) 27
German (24) 24
French (11) 11
Turkish (11) 11
Italian (8) 8
Russian (7) 7
Slovak (7) 7
Polish (3) 3
Czech (2) 2
Belarusian (1) 1
Croatian (1) 1
Hungarian (1) 1
Indonesian (1) 1
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text An Update on Existing and Emerging Data for Meropenem-Vaborbactam
by Shoulders, Bethany R and Casapao, Anthony M and Venugopalan, Veena
Clinical therapeutics, ISSN 0149-2918, 04/2020, Volume 42, Issue 4, pp. 692 - 702
carbapenemase-producing organisms | Klebsiella pneumonia carbapenemase | meropenem-vaborbactam | vaborbactam | multidrug-resistant gram-negative organisms | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Heterocyclic Compounds, 1-Ring - pharmacokinetics | Humans | Boronic Acids - adverse effects | Meropenem - adverse effects | Boronic Acids - chemistry | Meropenem - administration & dosage | Heterocyclic Compounds, 1-Ring - administration & dosage | Drug Interactions | Heterocyclic Compounds, 1-Ring - chemistry | Anti-Bacterial Agents - chemistry | Anti-Bacterial Agents - pharmacokinetics | Boronic Acids - pharmacokinetics | Heterocyclic Compounds, 1-Ring - adverse effects | Meropenem - pharmacokinetics | Anti-Bacterial Agents - adverse effects | Boronic Acids - administration & dosage | Meropenem - chemistry | Anti-Bacterial Agents - administration & dosage | Drug Combinations | Drug resistance in microorganisms | Pneumonia | Bacterial infections | Tazobactam | Bacterial pneumonia | Beta lactamases | Urinary tract infections | Permeability | Drug approval | Klebsiella | Enterobacter cloacae | Hemodialysis | Clinical trials | Carbapenemase | Organisms | Infections | Urinary tract | Drug resistance | Chloride | Bacterial diseases | E coli | Piperacillin | Bacteria | Pseudomonas aeruginosa | Meropenem | Drug dosages | Efflux | Enzymes | Pharmacodynamics | Drug interactions | Piperacillin-tazobactam | Pharmacology | FDA approval | Bacteremia | Chemotherapy | Acids | Antibiotics | Pyelonephritis | Minimum inhibitory concentration | Skin | Renal replacement therapy | Pharmacokinetics | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Pharmacodynamics of Meropenem against Acinetobacter baumannii in a neutropenic mouse thigh infection model
by Sabet, Mojgan and Tarazi, Ziad and Griffith, David C
Antimicrobial agents and chemotherapy, ISSN 0066-4804, 2020, Volume 64, Issue 4
Thigh model | Acinetobacter baumannii | Meropenem | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Microbiology | Science & Technology | Anti-Bacterial Agents - blood | Acinetobacter Infections - drug therapy | Bacterial Load | Colony Count, Microbial | Meropenem - blood | Microbial Sensitivity Tests | Animals | Anti-Bacterial Agents - pharmacokinetics | Meropenem - pharmacology | Meropenem - pharmacokinetics | Female | Anti-Bacterial Agents - pharmacology | Mice | Acinetobacter baumannii - drug effects | Acinetobacter Infections - microbiology | Disease Models, Animal | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Meropenem-vaborbactam: A new weapon in the war against infections due to resistant Gram-negative bacteria
by Patel, Twisha S and Pogue, Jason M and Mills, John P and Kaye, Keith S
Future microbiology, ISSN 1746-0913, 07/2018, Volume 13, Issue 9, pp. 971 - 983
carbapenem-resistant Enterobacteriaceae | Klebsiella pneumoniae carbapenemase | carbapenem | Gram-negative | β-lactamase inhibitor | β-lactam | β-lactamase | meropenem and vaborbactam | Life Sciences & Biomedicine | Microbiology | Science & Technology | Humans | Boronic Acids - adverse effects | Gram-Negative Bacterial Infections - drug therapy | Meropenem - adverse effects | Treatment Outcome | beta-Lactamase Inhibitors - pharmacology | Boronic Acids - therapeutic use | beta-Lactamase Inhibitors - pharmacokinetics | Meropenem - therapeutic use | Urinary Tract Infections - drug therapy | Anti-Bacterial Agents - therapeutic use | Clinical Trials, Phase III as Topic | beta-Lactamase Inhibitors - adverse effects | Drug-Related Side Effects and Adverse Reactions | beta-Lactamase Inhibitors - therapeutic use | Anti-Bacterial Agents - pharmacokinetics | Boronic Acids - pharmacokinetics | Meropenem - pharmacology | Meropenem - pharmacokinetics | Anti-Bacterial Agents - adverse effects | Anti-Bacterial Agents - pharmacology | Drug Combinations | Boronic Acids - pharmacology | Index Medicus
Journal Article
Details down arrow
4. Full Text Corrigendum to Physical Compatibility of Meropenem and Vaborbactam with Select Intravenous Drugs During Simulated Y-site Administration [Clinical Therapeutics 40 (2018) 261–269]
by Kidd, James M and Avery, Lindsay M and Asempa, Tomefa E and Nicolau, David P and Kuti, Joseph L
Clinical therapeutics, ISSN 0149-2918, 11/2018, Volume 40, Issue 11, pp. 1956 - 1956
Meropenem | Intravenous administration
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Plasma and synovial fluid pharmacokinetics of a single intravenous dose of meropenem in adult horses
by Langston, Vernon C and Fontenot, Robin L and Byers, Julie A and Andrews, Caroline M and Mochal‐King, Cathleen A
Journal of veterinary pharmacology and therapeutics, ISSN 0140-7783, 09/2019, Volume 42, Issue 5, pp. 525 - 529
horse | meropenem | antibacterial | pharmacokinetic | synovial fluid | Pharmacology & Pharmacy | Veterinary Sciences | Life Sciences & Biomedicine | Science & Technology | Anti-Bacterial Agents - blood | Area Under Curve | Half-Life | Meropenem - administration & dosage | Meropenem - blood | Synovial Fluid - chemistry | Horses - blood | Animals | Anti-Bacterial Agents - chemistry | Anti-Bacterial Agents - pharmacokinetics | Meropenem - pharmacokinetics | Meropenem - chemistry | Anti-Bacterial Agents - administration & dosage | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text In vivo efficacy of meropenem with a novel non--lactam–-lactamase inhibitor, nacubactam, against gram-negative organisms exhibiting various resistance mechanisms in a murine complicated urinary tract infection model
by Monogue, Marguerite L and Giovagnoli, Sara and Bissantz, Caterina and Zampaloni, Claudia and Nicolau, David P
Antimicrobial agents and chemotherapy, ISSN 0066-4804, 09/2018, Volume 62, Issue 9
Urinary tract infection | Meropenem-nacubactam | RG6080 | Meropenem | Gram-negative bacteria | Ceftazidime-avibactam | Nacubactam
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Meropenem/Vaborbactam, the First Carbapenem/β-Lactamase Inhibitor Combination
by Cho, Jonathan C and Zmarlicka, Monika T and Shaeer, Kristy M and Pardo, Joe
8/2018, Volume 52, Issue 8
bacterial infections | antibiotic resistance | infectious disease | antibiotics | urinary tract infections | Bacterial Infections - drug therapy | Humans | Boronic Acids - chemistry | Boronic Acids - therapeutic use | Meropenem - therapeutic use | Anti-Bacterial Agents - therapeutic use | Animals | Anti-Bacterial Agents - chemistry | Anti-Bacterial Agents - pharmacokinetics | Boronic Acids - pharmacokinetics | Meropenem - pharmacology | Meropenem - pharmacokinetics | Anti-Bacterial Agents - pharmacology | Meropenem - chemistry | Boronic Acids - pharmacology | Index Medicus
Book Review
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Mcr-1 and blakpc-3 in escherichia coli sequence type 744 after meropenem and colistin therapy, Portugal
by Tacão, Marta and Tavares, Rafael dos Santos and Teixeira, Pedro and Roxo, Inês and Ramalheira, Elmano and Ferreira, Sónia and Henriques, Isabel
Emerging infectious diseases, ISSN 1080-6040, 08/2017, Volume 23, Issue 8, pp. 1419 - 1421
Index Medicus | IncX4::mcr-1, IncF::Tn1441d-blaKPC-3, sequence type, Escherichia coli ST744, Klebsiella pneumoniae, multiresistance, Portugal, bacteria | and | Research Letter | Sequence Type 744 after Meropenem and Colistin Therapy, Portugal | gene, carbapenem, meropenem, colistin, polymixin, fluconazole, linezolid, co-resistance, antimicrobial resistance, antibacterial, antibiotic | antimicrobial | fluconazole | linezolid | antibacterial | Gene, carbapenem, meropenem, colistin, polymixin | co-resistance
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Single-dose pharmacokinetics and safety of meropenem-vaborbactam in subjects with chronic renal impairment
by Rubino, Christopher M and Bhavnani, Sujata M and Loutit, Jeffery S and Lohse, Brooke and Dudley, Michael N and Griffith, David C
Antimicrobial agents and chemotherapy, ISSN 0066-4804, 03/2018, Volume 62, Issue 3
Meropenem-vaborbactam | Renal impairment | Pharmacokinetics | Hemodialysis | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Microbiology | Science & Technology | Anti-Bacterial Agents - blood | Injections, Intravenous | Area Under Curve | Humans | Middle Aged | Half-Life | Kidney Failure, Chronic - urine | Male | Meropenem - blood | Glomerular Filtration Rate - physiology | Renal Insufficiency, Chronic - therapy | Meropenem - urine | Meropenem - pharmacokinetics | Adult | Female | Kidney Failure, Chronic - physiopathology | Drug Administration Schedule | Anti-Bacterial Agents - urine | Renal Insufficiency, Chronic - physiopathology | Kidney Failure, Chronic - therapy | Renal Insufficiency, Chronic - blood | Kidney Failure, Chronic - blood | Boronic Acids - urine | Anti-Bacterial Agents - pharmacokinetics | Boronic Acids - pharmacokinetics | Creatinine - blood | Aged | Drug Combinations | Boronic Acids - blood | Renal Dialysis | Renal Insufficiency, Chronic - urine | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Clinical cure rate and cost-effectiveness of carbapenem-sparing beta-lactams vs. meropenem for Gram-negative infections: A systematic review, meta-analysis, and cost-effectiveness analysis
by Nguyen, Chi Phuong and Dan Do, Thuc Nguyen and Bruggemann, Roger and ten Oever, Jaap and Kolwijck, Eva and Adang, Eddy M.M and Wertheim, Heiman F.L
International journal of antimicrobial agents, ISSN 0924-8579, 12/2019, Volume 54, Issue 6, pp. 790 - 797
Intra-abdominal infection | Urinary tract infection | Meropenem | Carbapenem-sparing beta-lactams | Extended-spectrum beta-lactamase | Pharmacology & Pharmacy | Infectious Diseases | Life Sciences & Biomedicine | Microbiology | Science & Technology | Anti-Bacterial Agents - economics | Anti-Bacterial Agents - therapeutic use | beta-Lactams - classification | Anti-Bacterial Agents - classification | Cost-Benefit Analysis | Humans | Gram-Negative Bacterial Infections - drug therapy | Meropenem - economics | Meropenem - classification | beta-Lactams - therapeutic use | Meropenem - therapeutic use | beta-Lactams - economics | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Spread of Meropenem-Resistant Streptococcus pneumoniae Serotype 15A-ST63 Clone in Japan, 2012-2014
by Nakano, Satoshi and Fujisawa, Takao and Ito, Yutaka and Chang, Bin and Matsumura, Yasufumi and Yamamoto, Masaki and Nagao, Miki and Suga, Shigeru and Ohnishi, Makoto and Ichiyama, Satoshi
Emerging infectious diseases, ISSN 1080-6040, 02/2018, Volume 24, Issue 2, pp. 275 - 283
Infectious Diseases | Immunology | Life Sciences & Biomedicine | Science & Technology | Microbial Sensitivity Tests | Japan - epidemiology | Pneumococcal Infections - epidemiology | Streptococcus pneumoniae - classification | Streptococcus pneumoniae - drug effects | Humans | Meropenem - pharmacology | Serogroup | Drug Resistance, Bacterial | Pneumococcal Infections - microbiology | Pneumonia | Analysis | Bacterial pneumonia | Cloning | Genomics | Genomes | Vaccines | Pharmaceutical industry | Health aspects | Index Medicus | PCV13 | bacteria | vaccines | Japan | Research | Streptococcus pneumoniae | Serotype 15A-ST63 Clone in Japan, 2012–2014 | PCV7 | antimicrobial resistance | ST63 | Spread of Meropenem-Resistant | serotype 15A | meropenem resistance | vaccination | pneumococcal conjugate vaccine
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Once-Daily Plazomicin for Complicated Urinary Tract Infections
by Wagenlehner, Florian M.E and Cloutier, Daniel J and Komirenko, Allison S and Cebrik, Deborah S and Krause, Kevin M and Keepers, Tiffany R and Connolly, Lynn E and Miller, Loren G and Friedland, Ian and Dwyer, Jamie P and EPIC Study Grp and EPIC Study Group
The New England journal of medicine, ISSN 0028-4793, 02/2019, Volume 380, Issue 8, pp. 729 - 740
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Drug Administration Schedule | Administration, Oral | Humans | Middle Aged | Male | Meropenem - adverse effects | Meropenem - administration & dosage | Urinary Tract Infections - drug therapy | Microbial Sensitivity Tests | Patient Acuity | Sisomicin - administration & dosage | Sisomicin - analogs & derivatives | Administration, Intravenous | Drug Resistance, Multiple, Bacterial | Enterobacteriaceae - drug effects | Adult | Female | Urinary Tract Infections - microbiology | Aged | Anti-Bacterial Agents - adverse effects | Sisomicin - adverse effects | Anti-Bacterial Agents - administration & dosage | Enterobacteriaceae Infections - drug therapy | Urinary tract infections | Enterobacter | Research | Drug therapy | Risk factors | Enterobacteriaceae | Creatinine | Enzymes | Intravenous administration | Bacterial infections | Hospital costs | Research & development--R&D | Multidrug resistance | Body weight | Urinary tract | Drug resistance | Patients | Urology | Bactericidal activity | Urinary tract diseases | Intravenous therapy | Antibiotics | CRE bacteria | Pyelonephritis | Meropenem | Urogenital system | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Meropenem-vaborbactam for adults with complicated urinary tract and other invasive infections
by Albin, Owen R and Patel, Twisha S and Kaye, Keith S
Expert review of anti-infective therapy, ISSN 1478-7210, 12/2018, Volume 16, Issue 12, pp. 865 - 876
meropenem-vaborbactam | Complicated urinary tract infection | CRE | multidrug-resistant gram-negative organisms | KPC | meropenem–vaborbactam | Pharmacology & Pharmacy | Infectious Diseases | Life Sciences & Biomedicine | Microbiology | Science & Technology | Klebsiella pneumoniae - isolation & purification | Enterobacteriaceae Infections - microbiology | Humans | Boronic Acids - adverse effects | Meropenem - adverse effects | Meropenem - administration & dosage | Urinary Tract Infections - drug therapy | Animals | Drug Resistance, Multiple, Bacterial | Meropenem - pharmacology | Adult | Urinary Tract Infections - microbiology | Anti-Bacterial Agents - adverse effects | Anti-Bacterial Agents - pharmacology | Boronic Acids - administration & dosage | Anti-Bacterial Agents - administration & dosage | Carbapenem-Resistant Enterobacteriaceae - drug effects | Drug Combinations | Boronic Acids - pharmacology | Enterobacteriaceae Infections - drug therapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Phase 1 study of the safety, tolerability, and pharmacokinetics of vaborbactam and meropenem alone and in combination following single and multiple doses in healthy adult subjects
by Rubino, Christopher M and Bhavnani, Sujata M and Loutit, Jeffery S and Morgan, Elizabeth E and White, Dan and Dudley, Michael N and Griffith, David C
Antimicrobial agents and chemotherapy, ISSN 0066-4804, 04/2018, Volume 62, Issue 4
Beta-lactamase | Drug interaction | Meropenem | Pharmacokinetics | Vaborbactam | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Microbiology | Science & Technology | Double-Blind Method | Drug Administration Schedule | Humans | Middle Aged | Boronic Acids - adverse effects | Male | Meropenem - adverse effects | Healthy Volunteers | Young Adult | Drug Interactions | Adolescent | Boronic Acids - pharmacokinetics | Meropenem - pharmacokinetics | Adult | Female | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights